What's Happening?
Spyre Therapeutics has announced the launch of its SPY772 program, which includes a combination of SPY072, an anti-TL1A antibody, and SPY007, an anti-IL-17A/F antibody. The company has also initiated the Phase 2 SKYLIGHT trial to evaluate the efficacy
of this combination in treating Hidradenitis Suppurativa (HS), a chronic skin condition. The trial aims to assess the dual inhibition of TL1A and IL-17A/F, with the goal of improving disease control and patient outcomes.
Why It's Important?
Hidradenitis Suppurativa is a painful and debilitating condition with limited treatment options. The SPY772 program represents a novel approach by targeting complementary inflammatory pathways, potentially offering improved efficacy over existing therapies. Successful outcomes from the SKYLIGHT trial could lead to a new standard of care for HS, addressing a significant unmet need and enhancing Spyre Therapeutics' position in the immunology market.
What's Next?
The SKYLIGHT trial will continue to enroll participants, with topline results expected by late 2027 or early 2028. Positive results could pave the way for further development and potential expansion of the SPY772 program to other inflammatory conditions. Spyre Therapeutics will monitor trial progress and engage with regulatory authorities to facilitate future approvals.
